# MRD-positive AML Clinical Study

> **NCT07131059** · NA · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 120 (estimated)

## Conditions studied

- AML, Adult

## Interventions

- **DRUG:** Ivosidenib
- **DRUG:** Gilteritinib
- **DRUG:** Venetoclax
- **DRUG:** Avapritinib
- **DRUG:** Daunorubicin
- **DRUG:** Cytarabine
- **DRUG:** Idarubicin
- **DRUG:** MTZ
- **DRUG:** HHT
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT07131059
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-11
- **Primary completion:** 2026-05-10
- **Final completion:** 2028-04-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07131059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07131059, "MRD-positive AML Clinical Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07131059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*